Pfizer offers lifeline: ongoing crizotinib access for cancer patients

NCT ID NCT05160922

Ongoing Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study allows people with certain cancers (NSCLC, ALCL, IMT) who are already benefiting from crizotinib in a previous Pfizer study to keep receiving the drug after that study ends. About 27 participants will continue treatment while doctors monitor for side effects. The goal is to provide ongoing access and gather more safety information.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anaplastic large cell lymphoma inflammatory myofibroblastic tumor non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALCL IMT NSCLC

Contacts and locations

Locations

ASST Monza

Monza, MB, 20900, Italy
Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China
Cancer Hospital Chinese Academy of Medical Science

Beijing, Beijing Municipality, 100021, China
Fujian Province Oncology Hospital

Fuzhou, Fujian, 350014, China
Jilin Cancer Hospital

Changchun, Jilin, 130028, China
Limited Liability Company "EuroCityClinic"

Saint Petersburg, 197022, Russia
National Hospital Organization Nagoya Medical Center

Nagoya, Aichi-ken, 460-0001, Japan
National Taiwan University Hospital

Taipei, 100, Taiwan
Shanghai Chest Hospital

Shanghai, 200030, China
Sun Yat-Sen University Cancer center

Guangzhou, Guangdong, 510060, China
The First Affiliated Hospital of College of Medicine,Zhejiang University

Hangzhou, Zhejiang, 310003, China
The First Affiliated Hospital of Guangzhou Medical University.

Guangzhou, Guangzhou, 510120, China
West China Hospital of Sichuan University

Wuhou District, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.